Walgreens Considers Selling Shields Health Solutions

Walgreens Considers Selling Shields Health Solutions

Walgreens Boots Alliance Inc. (WBA: NSD) is considering selling its subsidiary, Shields Health Solutions. This move is aimed at simplifying operations and giving more attention to its core business sectors. If the sale goes through, it could have a significant impact on the company’s future.

WBA Ratings by Stock Target Advisor

Stock Target Advisor’s Analysis on Walgreens:  

Analysts identified Walgreens’ stock (WBA: NSD) on hold, valuing the company’s stock at $27 – a prospective price change of 19.57% in the next 12 months. This is relatively higher than the $26.64 average analyst target price. Walgreens’ last closed stock price was $22.58. Interestingly, despite negative weekly and monthly trends (-0.29% and -3.64%, respectively), Walgreens’ stock price has dropped -37.10% over the past year, revealing a complicated picture.

Stock Target Advisor has identified several positive and negative signals from Walgreens. On the positive end, there is low volatility, underpricing compared to the book value, positive cash flow, superior returns on assets, high market capitalization, and good dividend returns. However, on the flip side, Walgreens has below median total returns and is overpriced on a cash flow basis. Being highly leveraged with negative free cash flow also raises concerns.

Pharmaceutical retailers in the “NSD” exchange, also have an average ‘Hold’ rating, as per Stock Target Advisor. Walgreens still emerges as one of the most significant players in the sector. 

walgreens

Walgreens: An Overview of Quarterly and Annual Financial Results

A look at Walgreens’ recent quarterly and annual financial figures paints a clearer picture of its financial condition. Despite posting $35.42 billion in revenue for the quarter ending in August 2023, the company recorded a net loss of $180 million, reflecting a profit margin of -0.51%. Furthermore, the net loss deepened to $3.08 billion for the year ending in August 2023, despite recording $139.08 billion in revenue.

 

Conclusion:

The potential sale of Shields Health Solutions may align with Walgreens’ strategic shift and the broader trend in healthcare towards streamlining operations. 

Top Trending Stocks

AVG Analyst Rating STA Analysis
StockTargetAdvisor
Buy
StockTargetAdvisor
Slightly Bullish
StockTargetAdvisor
Strong Buy
StockTargetAdvisor
Slightly Bullish
StockTargetAdvisor
Strong Buy
StockTargetAdvisor
Slightly Bullish
StockTargetAdvisor
Strong Buy
StockTargetAdvisor
Neutral
StockTargetAdvisor
Strong Buy
StockTargetAdvisor
Very Bullish
N/A
StockTargetAdvisor
Bearish
StockTargetAdvisor
Strong Buy
StockTargetAdvisor
Neutral
StockTargetAdvisor
Strong Buy
StockTargetAdvisor
Slightly Bullish
StockTargetAdvisor
Strong Buy
StockTargetAdvisor
Bullish
StockTargetAdvisor
Strong Buy
StockTargetAdvisor
Neutral
Ad
Ad

Leave a Reply

Your email address will not be published. Required fields are marked *